newsfilter
← Latest News
PR Newswire·

Positive Top-Line Results for Bimekizumab in Phase 3 Ankylosing Spondylitis Trial

BRUSSELS and ATLANTA, Dec. 16, 2021 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced positive top-line interim analysis results from the Phase 3 BE MOBILE 2 study, which is evaluating the efficacy and safety of bimekizumab in ad